期刊
JOURNAL OF CONTROLLED RELEASE
卷 190, 期 -, 页码 172-181出版社
ELSEVIER SCIENCE BV
DOI: 10.1016/j.jconrel.2014.06.043
关键词
Eye; Drug delivery; Barriers; Targeting; Macromolecules; Controlled release
资金
- National Eye Institute [R24-EY017045, R01-EY022097]
- National Natural Science Foundation of China [81000369, 81271036]
- NATIONAL EYE INSTITUTE [R24EY017045, R01EY022097, P30EY006360, F30EY025154, T32EY007092] Funding Source: NIH RePORTER
- NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008169] Funding Source: NIH RePORTER
Biopharmaceuticals are making increasing impact on medicine, including treatment of indications in the eye. Macromolecular drugs are typically given by physician-administered invasive delivery methods, because non-invasive ocular delivery methods, such as eye drops, and systemic delivery, have low bioavailability and/or poor ocular targeting. There is a need to improve delivery of biopharmaceuticals to enable less-invasive delivery routes, less-frequent dosing through controlled-release drug delivery and improved drug targeting within the eye to increase efficacy and reduce side effects. This review discusses the barriers to drug delivery via various ophthalmic routes of administration in the context of macromolecule delivery and discusses efforts to develop controlled-release systems for delivery of biopharmaceuticals to the eye. The growing number of macromolecular therapies in the eye needs improved drug delivery methods that increase drug efficacy, safety and patient compliance. (C) 2014 Elsevier B.V. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据